Lei Stanley Qi
Chemical and systems biology researcher
From Wikipedia, the free encyclopedia
Lei "Stanley" Qi (Chinese: 亓磊; pinyin: Qí Lěi) is an associate professor in the department of bioengineering, and the department of chemical and systems biology at Stanford University. Qi led the development of the first catalytically dead Cas9 lacking endonuclease activity (dCas9), which is the basis for CRISPR interference (CRISPRi). His laboratory subsequently developed CRISPR-Genome Organization (CRISPR-GO) based on dCas9[1] and CRISPR-Transcriptome Organization (CRISPR-TO) based on dCas13.[2]
- Tsinghua University (B.A.)
- UC Berkeley (Ph.D.)
- Sloan Research Fellowship (2017)
- Pew Scholar (2016)
- NIH Directors Early Independence Award (2013)
Lei Stanley Qi | |
|---|---|
| |
| Born | Qi Lei (亓磊) |
| Alma mater |
|
| Known for | CRISPRi, dCas9，CRISPR imaging，CRISPR-GO |
| Awards |
|
| Scientific career | |
| Fields | Genome engineering, Synthetic Biology |
| Institutions | Stanford, Chemical and Systems Biology |
| Academic advisors | Adam Arkin, Jennifer Doudna |
| Website | |
Qi is a co-inventor of the University of California patent on the CRISPR gene-editing technology.
Early life and education
Qi obtained his B.S. in physics and math from Tsinghua University,[3] China, Master in physics from UC Berkeley, and PhD in bioengineering from UC Berkeley.[4] During his PhD work at Berkeley, he studied synthetic biology with Adam Arkin, and was the first to explore engineering the CRISPR for targeted gene editing and gene regulation with Jennifer Doudna.[5] After PhD, he performed independent research work as a faculty fellow at UCSF.[6] He joined the Stanford faculty in 2014.[7] [8] [9] [10] [11] [12] [13]